Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center


Ball - Ambassadors

Sydney Ball
Sydney Ball

I joined the Vanderbilt-Ingram Cancer Center Ambassadors in 2017 through the Young Leaders Council Leadership Program. The VICC Ambassadors are an amazing group of passionate individuals that I am thankful to have the opportunity to partner alongside in the fight against cancer. Our experience together has been incredible; the influence we have made has been significant; and the friendships we have formed have been endearing.

I think everyone has been impacted, at some level, by cancer. However, cancer had a dramatic impact on my life in 2016 when my grandfather lost his fight to lung cancer and my cousin died of an undiagnosed metastatic cancer. Being able to raise awareness about cancer research through the VICC Ambassadors has been a meaningful way for me to give back to the community, while also awarding discovery grants for a cause that has closely impacted my family.

As part of the VICC Ambassadors, you will have the opportunity to be educated on trends in medical research, vote on where the research dollars are distributed, and help raise awareness for innovative philanthropic efforts. We look forward to you partnering with us on this journey and hope you will participate in any way that you can!


SMART Precision Cancer Medicine

A diagnosis of cancer is a life-changing event whi

Hertha - Ambassadors

Erin Hertha
Erin Hertha

The mission to find a cure for cancer is something I strongly believe in and value. Most of us have our own stories about how cancer has affected someone we loved dearly. My story is about my mother, who was diagnosed with lung cancer in 2001. At the time, we lived in a small city where there was not a powerful resource like Vanderbilt-Ingram Cancer Center. The doctors tried to do what they could, but her advanced cancer was past the point of intervention. My mother lost her battle on November 10, 2001, two months after my 13th birthday. Cancer left a void in my heart by taking one of the people I loved most in the world.  

Eighteen years later, my path led me to Vanderbilt-Ingram Cancer Center where I work under the incredible leadership of Jennifer Pietenpol, PhD. The work, passion and devotion I witness daily from Dr. Pietenpol, leadership and staff in Vanderbilt-Ingram show me why we are the leader in prevention, diagnosis and treatment of cancer. 

I joined VICC Ambassadors because of my passion for finding cures and my belief in this program. My story may not have had the ending I hoped for, but I am optimistic that the VICC Ambassadors can help make great strides toward giving others better endings to their stories.
 


Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Multiple Cancer Types

The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Lung, Non Small Cell
II
Horn, Leora
NCT02706626
VICCTHO1736

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3 / Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Leukemia

The purpose of this study is to compare relapse-free survival between participants with FLT3 / ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.
Leukemia
III
Byrne, Michael
NCT02997202
VICCBMT1740

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Multiple Cancer Types

The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas. Patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule). Treatment will continue until disease progression or until another criterion for withdrawal is met. .Efficacy will be measured by evaluating the tumor's objective response rate. Radiological tumor assessments will be performed at defined time points until the patient's disease progresses. Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival or fresh biopsy tissue will also be collected for mesothelin expression testing and biomarker analyses.
Breast, Endocrine, Esophageal, Gastrointestinal, Lung, Non Small Cell, Pancreatic
I
Horn, Leora
NCT03102320
VICCPHI1742

Tumor-Treating Fields Therapy in Preventing Brain Tumors in Patients with Extensive-Stage Small Cell Lung Cancer

Multiple Cancer Types

This trial studies how well tumor-treating fields therapy works in preventing brain tumors in patients with small cell lung cancer that has spread to other places in the body. Tumor-treating fields therapy involves the use of the NovoTTF-200A which delivers alternating electrical fields, or tumor treating fields, through ceramic discs placed on the head. This electric force may slow and / or reverse tumor growth by disrupting the way cancer cells grow.
Lung, Small Cell
N/A
Attia, Albert
NCT03607682
VICCTHO1747

M3541 in Combination With Radiotherapy in Subjects With Solid Tumors

Multiple Cancer Types

This dose-escalation study will evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated palliative radiotherapy (RT) in subjects with solid tumors with malignant lesions in the thorax, abdominal cavity, head and neck region, or extremities likely to benefit from palliative RT.
Esophageal, Gastric/Gastroesophageal, Gastrointestinal, Head/Neck, Lung, Miscellaneous, Phase I
I
Not Available
NCT03225105
VICCPHI1748

Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Primitive Neuro-ectodermal Tumors

Neuroblastoma (Pediatrics)

This phase IV trial studies how well standard chemotherapy works in treating young patients with medulloblastoma or other central nervous system primitive neuro-ectodermal tumors. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Neuroblastoma (Pediatrics)
IV
Esbenshade, Adam
NCT02875314
VICCPED1751

Lenalidomide with or without Ixazomib Citrate and Dexamethasone in Treating Patients with Residual Multiple Myeloma after Donor Stem Cell Transplant

This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells and may also prevent the growth of new blood vessels that are needed for cancer growth. Ixazomib citrate may stop the growth of cancer cells by interfering with proteins necessary for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether lenalidomide is more effective with or without ixazomib citrate and dexamethasone in treating residual multiple myeloma.
Not Available
II
Cornell, Robert
NCT02389517
VICCPCL1848

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: